CADL vs. JSPR, BDTX, URGN, SOPH, CRBU, MGTX, IVVD, ADAP, TNYA, and PSTX
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Jasper Therapeutics (JSPR), Black Diamond Therapeutics (BDTX), UroGen Pharma (URGN), SOPHiA GENETICS (SOPH), Caribou Biosciences (CRBU), MeiraGTx (MGTX), Invivyd (IVVD), Adaptimmune Therapeutics (ADAP), Tenaya Therapeutics (TNYA), and Poseida Therapeutics (PSTX). These companies are all part of the "medical" sector.
Jasper Therapeutics (NASDAQ:JSPR) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
In the previous week, Jasper Therapeutics had 16 more articles in the media than Candel Therapeutics. MarketBeat recorded 23 mentions for Jasper Therapeutics and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.91 beat Jasper Therapeutics' score of 0.81 indicating that Jasper Therapeutics is being referred to more favorably in the media.
Jasper Therapeutics currently has a consensus price target of $64.29, suggesting a potential upside of 179.26%. Candel Therapeutics has a consensus price target of $11.00, suggesting a potential downside of 4.35%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Candel Therapeutics.
Jasper Therapeutics received 18 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 83.87% of users gave Jasper Therapeutics an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Candel Therapeutics has higher revenue and earnings than Jasper Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 2.7% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 44.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Jasper Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500.
Candel Therapeutics' return on equity of -64.58% beat Jasper Therapeutics' return on equity.
Summary
Jasper Therapeutics beats Candel Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
